Welcome to our dedicated page for Zenas BioPharma SEC filings (Ticker: ZBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zenas BioPharma, Inc. (Nasdaq: ZBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zenas is a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, and its filings document key aspects of its business, including stock exchange listing details, financing arrangements, licensing agreements and clinical development updates.
Recent Form 8-K filings describe material events such as the revenue participation and funding agreement with Royalty Pharma related to obexelimab, under which Royalty Pharma will provide up to $300 million in consideration in exchange for specified royalty and revenue participation rights. Other 8-Ks detail the license agreement with InnoCare Pharma granting Zenas exclusive rights to develop, manufacture and commercialize orelabrutinib in the multiple sclerosis field globally and non-oncology indications outside certain territories, as well as rights to ZB021 and ZB022. Additional current reports cover private placement financings, adoption of the 2026 Inducement Plan for equity awards, and press releases furnishing quarterly financial results.
Through this page, users can review how Zenas reports its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ZBIO, and the terms of material definitive agreements that shape its capital structure and pipeline strategy. Filings linked here include exhibits such as inducement equity plans, option and restricted stock unit agreements, subscription and registration rights agreements, and revenue participation contracts, which provide further detail on governance and compensation frameworks.
Stock Titan enhances these documents with AI-powered summaries that explain the significance of each filing in clear language. As new 8-Ks, 10-Qs, 10-Ks and other forms become available on EDGAR, they are incorporated so investors can quickly see how developments in obexelimab, orelabrutinib, ZB021 and ZB022, as well as financing and licensing transactions, are reflected in Zenas BioPharma’s official regulatory record.
Leon O. Moulder, Jr. and related entities report updated ownership in Zenas BioPharma, Inc. following recent share purchases. They now beneficially own 3,029,921 shares of common stock, representing 4.794% of the class, including shares held directly, through options, and via Tellus BioVentures, LLC and a revocable trust.
On February 2, 2026, Mr. Moulder purchased 57,000 shares in open-market transactions at prices between $17.69 and $18.14 per share. Between March 30 and March 31, 2026, Tellus purchased 54,000 shares in open-market transactions at prices between $18.195 and $19.58 per share.
Zenas BioPharma director-affiliated investment funds made an open-market purchase of 3,768 shares of common stock at $18.63 per share. After this transaction, entities associated with Hongbo Lu indirectly held 426,736 shares. The filing notes these securities are owned directly by NEXTBio funds, and Lu disclaims beneficial ownership beyond any pecuniary interest.
Fairmount Healthcare Fund II L.P., an entity associated with Fairmount Funds Management, reported an open-market purchase of 150,000 shares of Zenas BioPharma, Inc. common stock at $20.00 per share. After this transaction, the fund indirectly held 2,359,025 shares of Zenas BioPharma common stock.
Fairmount Funds Management LLC acts as investment manager to the fund, and its managers, Peter Harwin and Tomas Kiselak, along with Fairmount, disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
Zenas BioPharma, Inc. chief executive officer–associated entities increased their holdings through open-market purchases of Common Stock. Entities associated with Leon O. Moulder, Jr. bought 20,000 shares on March 30 at a weighted average price of $18.23 per share and 34,000 shares on March 31 at a weighted average price of $19.31 per share, for a total of 54,000 shares. After these transactions, one indirect account held 1,726,039 shares, while another indirect trust account held 36,928 shares and a direct account held 423,155 shares. Footnotes explain that these shares are held by Tellus BioVentures LLC and a revocable trust, where Moulder may be deemed to have voting and dispositive power but disclaims beneficial ownership beyond his pecuniary interest.
Zenas BioPharma, Inc. director-associated investment entities acquired additional common stock in an underwritten public offering. Entities affiliated with Hongbo Lu purchased 75,000 shares of common stock at $20.00 per share, and now hold 422,968 shares indirectly after the transaction. The securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC, with various NEXTBio management entities and Hongbo Lu potentially deemed indirect beneficial owners, subject to a formal disclaimer of beneficial ownership beyond any pecuniary interest.
Zenas BioPharma, Inc. completed two financings: a public offering of $200 million in 2.50% Convertible Senior Notes due 2032 and an equity offering of 5,000,000 common shares at $20.00 per share. The notes bear 2.50% annual interest, payable semiannually, and are convertible at an initial rate of 37.7358 shares per $1,000 of principal, with customary anti-dilution and make-whole adjustments. The company may redeem the notes after April 8, 2030 if stock price conditions are met, and holders have repurchase rights upon specified “Fundamental Change” events. Net proceeds were approximately $193.7 million from the notes and $93.7 million from the equity, which the company intends to use to support the planned U.S. commercial launch of obexelimab for IgG4-RD, advance its pipeline (including orelabrutinib and ZB021 trials), and for working capital and general corporate purposes. The company also reiterates previously disclosed risks, including that its auditors have expressed substantial doubt about its ability to continue as a going concern.
Zenas BioPharma is offering $200,000,000 aggregate principal amount of 2.50% convertible senior notes due 2032, with an underwriter option for up to $30,000,000 of additional notes. Interest accrues at 2.50% paid semi‑annually; maturity is April 1, 2032. The initial conversion rate is 37.7358 shares per $1,000 principal (approximately $26.50 per share). Conversions may be settled in cash, shares or a combination, and are permitted only upon specified triggers prior to January 1, 2032 and freely thereafter until maturity. The notes are unsecured senior obligations, effectively subordinated to secured debt and structurally subordinated to subsidiary liabilities. Expected net proceeds are approximately $193.7 million; intended uses include funding a potential U.S. commercial launch for obexelimab and advancing clinical programs.
Zenas BioPharma is registering a primary offering of 5,000,000 shares of common stock. The prospectus supplement states a public offering price of $20.00 per share for gross proceeds of $100,000,000 and estimated net proceeds to the company of approximately $94.0 million before expenses; the underwriters have a 30-day option to purchase an additional 750,000 shares.
The filing describes a concurrent public offering of 2.50% Convertible Senior Notes due 2032 in an aggregate principal amount of $200.0 million (or $230.0 million if the over-allotment is exercised). The supplement discloses recent positive Phase 3 topline results for obexelimab in IgG4-RD and a planned BLA submission in Q2 2026, and states the company expects the combined proceeds, existing cash, ATM sales and first tranche loan to fund operations into Q3 2028.
Zenas BioPharma is pursuing a securitized capital raise via an offering of convertible senior notes due 2032 and a concurrent equity offering. The company reported positive Phase 3 obexelimab results in IgG4-RD (56% reduction in risk of flare; Hazard Ratio 0.44, p=0.0005) and plans to submit a BLA in Q2 2026.
Earlier Phase 2 MoonStone RMS data showed a sustained reduction in new GdE T1 lesions through week 24. The company is advancing orelabrutinib into global Phase 3 programs (PriMroSe and Monarch) and expects to initiate additional IND-directed Phase 1 studies for ZB021 and ZB022 in 2026. Separately, Zenas entered a Loan Agreement providing for up to $250.0 million in term loans with an initial Tranche A of $75.0 million. The prospectus supplement describes conversion, redemption and repurchase features, ranking and material risks; offering size and many pricing fields are left blank in the provided excerpt.
Zenas BioPharma is offering shares of its common stock and is conducting a concurrent convertible notes offering. The prospectus supplement describes the proposed equity offering on an automatic shelf registration and a separate, concurrent public offering of convertible senior notes due 2032.
The company reported positive Phase 3 obexelimab results in January 2026 (Hazard Ratio 0.44, p=0.0005) and plans to submit a BLA for IgG4-RD in Q2 2026. It also reported confirmatory RMS Phase 2 data and expects topline SLE Phase 2 results in Q4 2026. On March 14, 2026, the company entered a loan agreement providing up to $250.0 million in term loans. The prospectus states intended uses of proceeds: support a potential U.S. commercial launch for obexelimab, advance orelabrutinib Phase 3 trials, fund ZB021 development, and for general corporate purposes.